Updated:
Turnstone Biologics Corp.
Turnstone Biologics was founded in 2015 and is headquartered in Stockholm, Sweden, with an additional office in La Jolla, California.
Turnstone Biologics Corp.
Turnstone Biologics was founded in 2015 and is headquartered in Stockholm, Sweden, with an additional office in La Jolla, California. The firm's origins trace back to academic research in TIL therapy, and it operates as a clinical-stage biotechnology company rather than a traditional family office. Its lead program, TIDAL-01, is an investigational TIL therapy for multiple solid tumor indications. The company's strategy centers on its proprietary TIL selection platform, which identifies and expands tumor-reactive T cells from patient biopsies. Key assets include TIDAL-01, which entered Phase 1/2 clinical trials in 2021 for indications such as melanoma and colorectal cancer (per the firm's public communications, 2021). The firm collaborates with academic institutions and contract research organizations to conduct its trials, focusing on immunotherapy-resistant tumors. Its geographic footprint spans North America and Europe, with clinical trial sites in the United States and Europe. Turnstone Biologics has not publicly disclosed total funding or a dedicated investment professional count. It raised capital through Series A, B, and C rounds from healthcare-focused investors, though specific names and amounts are not confirmed in the available record. The company maintains a presence on social media via LinkedIn (unconfirmed capture) and its corporate website, which outlines its pipeline and scientific approach. Recent operational activity includes the announcement of interim Phase 1/2 data in December 2023 for TIDAL-01 in colorectal cancer (per the firm's press release, December 2023). Turnstone Biologics distinguishes itself from conventional cell therapy firms by employing a biomarker-driven TIL selection process rather than the indiscriminate expansion commonly used. This approach aims to increase the proportion of tumor-specific T cells in the final product, potentially reducing toxicity and improving efficacy. The company holds patents covering its TIL selection methodology, which it licenses from academic research institutions.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Sweden
City
Stockholm
Corporate office
Stockholm, Sweden
Additional offices
La Jolla, CA, United States
Sector focus
Frequently asked questions
What is Turnstone Biologics' investment focus?
Turnstone Biologics is a clinical-stage biotechnology company developing tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. It does not function as an investment firm; its focus is on drug development in immuno-oncology. The company's pipeline targets cancers such as melanoma and colorectal cancer, where standard therapies have limited efficacy.
Who leads Turnstone Biologics' clinical development?
The firm's executive team includes a Chief Medical Officer and a Chief Scientific Officer, though names are not confirmed in the available record. Clinical development is managed internally with oversight from a board of directors comprising individuals from the biotech and venture capital sectors. The company has not disclosed specific investment decision-makers as it is a biotechnology firm, not a family office.
How does Turnstone Biologics source its technology?
Turnstone Biologics' TIL selection platform is based on academic research from institutions including the University of Texas MD Anderson Cancer Center and the Karolinska Institute (per public record, 2015). The company licenses foundational patents related to T cell selection and expansion. This intellectual property forms the core of its proprietary approach to developing personalized cell therapies.
Is Turnstone Biologics structured as a family office or a public company?
Turnstone Biologics is a privately held biotechnology corporation, not a family office or asset manager. It is funded by venture capital and private equity investments from healthcare funds. The firm does not manage capital for external investors or family principals; its operations are typical of a clinical-stage biotech company with a focus on R&D and regulatory milestones.
What therapeutic areas does Turnstone Biologics target?
Turnstone Biologics focuses exclusively on immuno-oncology, specifically developing TIL therapies for solid tumors. Its lead indication is metastatic colorectal cancer, which entered clinical trials in 2021, alongside melanoma. The company's platform aims to overcome resistance to checkpoint inhibitors by delivering tumor-specific T cells. It does not engage in other disease areas like autoimmune or infectious disease.
Does Turnstone Biologics publish financial data or AUM?
As a private biotech company, Turnstone Biologics does not disclose AUM or similar financial metrics. It reports clinical trial results and pipeline milestones through press releases and corporate communications. Funding rounds have included Series A, B, and C, but specific amounts and investor names are not publicly verifiable from the available sources.
Where are Turnstone Biologics' clinical trials conducted?
Turnstone Biologics operates clinical trial sites in the United States and Europe. The company's Stockholm office oversees European regulatory and clinical activities, while the La Jolla office handles US operations. Trials are conducted in partnership with academic medical centers and contract research organizations, focusing on patients with advanced solid tumors.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: